Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Trinity Biotech stock

Learn how to easily invest in Trinity Biotech stock.

Trinity Biotech plc is a diagnostics & research business based in the US. Trinity Biotech shares (TRIB) are listed on the NASDAQ and all prices are listed in US Dollars. Trinity Biotech employs 477 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Trinity Biotech

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – TRIB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Trinity Biotech stock price (NASDAQ: TRIB)

Use our graph to track the performance of TRIB stocks over time.

Trinity Biotech shares at a glance

Information last updated 2022-07-03.
Latest market close$1.30
52-week range$0.86 - $3.05
50-day moving average $1.26
200-day moving average $1.47
Wall St. target price$4.00
PE ratio 33
Dividend yield $0 (0%)
Earnings per share (TTM) $0.04

Buy Trinity Biotech shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Stocks, ETFs, Cryptocurrency
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you open a Robinhood account
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Axos Bank Self Directed Investing
when you open an account and deposit at least $1500.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Trinity Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Trinity Biotech price performance over time

Historical closes compared with the close of $1.3 from 2022-07-06

1 week (2022-06-30) 5.69%
1 month (2022-06-07) -5.80%
3 months (2022-04-07) 30.00%
6 months (2022-01-07) -0.76%
1 year (2021-07-07) -49.22%
2 years (2020-07-07) -48.82%
3 years (2019-07-05) 1.7
5 years (2017-07-07) 5.7

Is Trinity Biotech stock undervalued or overvalued?

Valuing Trinity Biotech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Trinity Biotech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Trinity Biotech's P/E ratio

Trinity Biotech's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 33x. In other words, Trinity Biotech shares trade at around 33x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Trinity Biotech's PEG ratio

Trinity Biotech's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.3. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Trinity Biotech's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Trinity Biotech's EBITDA

Trinity Biotech's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $7.7 million.

The EBITDA is a measure of a Trinity Biotech's overall financial performance and is widely used to measure a its profitability.

Trinity Biotech financials

Revenue TTM $86.1 million
Operating margin TTM 6.96%
Gross profit TTM $38.1 million
Return on assets TTM 3.1%
Return on equity TTM -190.56%
Profit margin -15.1%
Book value $0.04
Market capitalisation $50.3 million

TTM: trailing 12 months

Trinity Biotech share dividends

We're not expecting Trinity Biotech to pay a dividend over the next 12 months.

Have Trinity Biotech's shares ever split?

Trinity Biotech's shares were split on a 1:4 basis on 1 June 2005. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Trinity Biotech shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Trinity Biotech shares which in turn could have impacted Trinity Biotech's share price.

Trinity Biotech share price volatility

Over the last 12 months, Trinity Biotech's shares have ranged in value from as little as $0.86 up to $3.05. A popular way to gauge a stock's volatility is its "beta".

TRIB.US volatility(beta: 1.32)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Trinity Biotech's is 1.3203. This would suggest that Trinity Biotech's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Trinity Biotech overview

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland. .

Frequently asked questions

What percentage of Trinity Biotech is owned by insiders or institutions?
Currently 11.631% of Trinity Biotech shares are held by insiders and 43.15% by institutions.
How many people work for Trinity Biotech?
Latest data suggests 477 work at Trinity Biotech.
When does the fiscal year end for Trinity Biotech?
Trinity Biotech's fiscal year ends in December.
Where is Trinity Biotech based?
Trinity Biotech's address is: IDA Business Park, Bray, Ireland
What is Trinity Biotech's ISIN number?
Trinity Biotech's international securities identification number is: US8964383066
What is Trinity Biotech's CUSIP number?
Trinity Biotech's Committee on Uniform Securities Identification Procedures number is: 896438108

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site